Barry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $30.12 on Friday. The stock has a market capitalization of $1.88 billion, a P/E ratio of -10.72 and a beta of 1.17. The company has a 50-day moving average price of $32.66 and a 200-day moving average price of $32.34. Stoke Therapeutics, Inc. has a 1 year low of $10.64 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. RTW Investments LP increased its holdings in Stoke Therapeutics by 8.3% during the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares during the period. Redmile Group LLC increased its stake in Stoke Therapeutics by 3.2% during the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after purchasing an additional 130,050 shares in the last quarter. Morgan Stanley grew its stake in shares of Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after acquiring an additional 9,108 shares during the period. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Canaccord Genuity Group boosted their target price on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Wedbush boosted their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Finally, Guggenheim assumed coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They issued a “buy” rating and a $60.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.